Vaccine Development

Moderna Clinical Trials Market Impact mRNA Technology Funding Novavax Market Reactions Research and Development Corporate Governance Manufacturing Collaboration Agreements Contracts Moderna Inc. AstraZeneca Research Funding COVID-19 Vaccines COVID-19 Vaccine Clinical Research Pricing Strategies Covid-19 Vaccines Corporate Deals Cancer Vaccine Research and Trials Regulatory Affairs Market Response Seattle-based Investment Decisions Manufacturing Agreements Market Performance Manufacturers Company Acquisitions Valneva Valneva SE Technology Transfer Corporate Communication Pfizer Acquisitions Public Health Response Market Competition

12 ARTICLES

4w ago

Moderna Starts Phase 1 Trial in Canada for Bundibugyo Ebola Vaccine

The move launches rapid safety testing for a strain with no approved vaccine; favorable early results would allow larger trials and shape potential supply for low‑income countries.

7 ARTICLES

5mo ago

Pfizer and BioNTech Halt U.S. COVID Vaccine Trial for 50–64-Year-Olds Over Slow Enrollment

5 ARTICLES

8mo ago

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

11 ARTICLES

last yr.

FDA Suspends Valneva’s Ixchiq Chikungunya Vaccine Over Safety Reports

4 ARTICLES

last yr.

Moderna’s mRNA-1010 Flu Vaccine Outperforms Standard Shot and Advances Toward Approval

6 ARTICLES

last yr.

FDA Expands Moderna RSV Vaccine to Adults 18–59 at Risk

10 ARTICLES

last yr.

FDA Approves Moderna’s mNEXSPIKE for Seniors and High-Risk Adults as CDC Drops Recommendations for Healthy Children and Pregnant Women

30 ARTICLES

last yr.

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

4 ARTICLES

last yr.

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

16 ARTICLES

last yr.

FDA Grants Limited Approval to Novavax’s COVID-19 Vaccine